United States: FDA Issues Draft Guidance For Regulation Of LDTs

On September 30th, 2014 the U.S. Food and Drug Administration published the draft guidance entitled "Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs)" ("Guidance"). The publication of the draft Guidance is the next step in FDA's implementation of its risk based approach to oversight of LDTs. In addition to noting FDA's intention for bringing under its review many devices or tests that previously were exempt under the FDA's enforcement discretion, the FDA's draft Guidance also imposes new requirements, such as registration and notice, for all LDTs.

This post summarizes the proposed new categories of LDTs, the new notice requirements, and FDA's implementation timeline as set forth in the draft Guidance.

Device Categories

Medical devices are classified as Class I, II or III, based upon controls necessary to provide a reasonable assurance of the safety and effectiveness of the device. Guidance at page 11. The intended use of the device, technological characteristics, and patient risk should the device fail, are additional considerations for device classification. Guidance at page 11.

The Guidance indicates that FDA will rely on the existing medical device classification system to evaluate the risk of the LDT and rely on input from industry experts to classify devices not previously classified by FDA. Guidance at page 12. FDA will issue an additional draft guidance within 18 months of the finalization of the Guidance (final guidance) to inform the public of what it considers generally to be Class I, II or III. The final guidance should issue within 24 months of finalization of the Guidance. Guidance at page 26.

FDA defines the term laboratory developed test as an in vitro diagnostic that is intended for clinical use that is designed, manufactured, and used within a single laboratory. The Guidance provides the following as an example of an LDT:

"A laboratory uses peer reviewed articles to guide development of a new diagnostic device. The laboratory uses general purpose reagents and analyte specific reagents combined with general laboratory instructions and develops a testing protocol, that together constitute a test system that is then verified and validated within the laboratory. Once validated this device is used by the laboratory to provide clinical diagnostic results."

Guidance at page 5.

Thus, FDA does not consider tests or devices that are designed or manufactured completely or partly outside the laboratory that offers and uses them as LDTs. The Guidance also recognizes that tests may be offered as LDTs even though they do not meet FDA's definition of LDT. However, the Guidance indicates that FDA intends to apply a risk based approach to any in vitro diagnostic that is offered as an LDT by a CLIA-certified laboratory in the interest of ensuing continuity in the testing market and patient access to the tests.

Continued Enforcement Discretion and Minimal Requirements For Certain Devices

Certain LDTs, such as those used solely for forensic purposes and those used in connection with tissue transplantation when used in a CLIA-certified laboratory, will be exempt from FDA oversight for all applicable regulatory requirements (exempt devices).

The Guidance states that FDA intends to exercise enforcement discretion for applicable premarket review requirements and quality system requirements for the following devices:

  • Low-risk LDTs (Class I devices);
  • LDTs for rare diseases;
  • LDTs that fall within the traditional definition of LDT, as described above; and
  • LDTs for unmet needs, when no FDA-approved or cleared equivalent device is available for the unmet need.

Notice and Basic Information

With the exception of the exempt devices, all manufacturers of LDTs are required to provide notice and basic information to the FDA regarding their tests, such as notice of manufacturing and provide basic information regarding such devices. Notification to FDA is expected to occur once for each LDT, unless significant changes are made to the test. For LDTs currently on the market or those to be launched within 6 months of the publication of the final guidance, the manufacturer of the LDT should provide notice to the FDA within 6 months of publication of the final guidance. If a new LDT is to be launched after 6 months from publication of the final guidance, notification must be provided to the FDA prior to offering the LDT for clinical use. The Guidance notes that when the manufacturer makes a significant change to the LDT, it is considered to be a new device and therefore new notification is required prior to offering the LDT for clinical use. Guidance at page 17.

If notification and listing is not provided to the FDA for a LDT within the appropriate timeframe, it is assumed that the laboratory will have opted not to be within the scope of the FDAs enforcement discretion policy with respect to the registration and listing requirements.

In addition to the notification requirements noted above, the Guidance indicates that the FDA intends to enforce the manufacturer reporting requirements of the Medical Device Reporting (MDR) regulation (21 CFR Part 803, Subpart E) that is, to submit reports to FDA of adverse events i.e., if the use of the device contributed to the death or serious injury of a patient. Adverse event reporting for LDTs should begin 6 months following publication of the final guidance.

Guidance at page 19.

Premarket Review Requirements

The Guidance states that with the exception of the exempt devices, FDA intends to phase in the enforcement of applicable premarket requirements over time based on the risk associated with the device. Guidance at page 20.

For laboratories that manufacture traditional LDTs, FDA intends to continue to exercise enforcement discretion with respect to premarket review requirements.

High and Moderate Risk LDT

The Guidance states that for high risk and moderate risk LDTs, FDA intends to enforce applicable regulatory requirements, including registration and listing (with the option to instead provide notification, discussed above), adverse event reporting, premarket review and quality system requirements as noted below.

High-risk LDTs (Class III devices) are to be reviewed as follows. Registration and listing (with the option to provide notification) of the LDT and adverse event reporting are to begin 6 months after publication of the final guidance. Premarket review requirements are to begin 12 months after publication of the final guidance and phased-in over 4 years for the remaining high-risk devices. Devices can remain on the market during review and FDA's consideration of applications to ensure patient access to the devices.

FDA's focus on high-risk devices begins with the following:

  1. LDTs with the same intended use as an FDA-approved companion diagnostic;
  2. LDTs with the same intended use as an FDA-approved Class III medical device; and
  3. Certain LDTs for determining the safety or efficacy of blood or blood products.

FDA's focus on moderate-risk LDTs (Class II devices) is as follows. Registration and listing (with the option to provide notification) of the LDT and adverse event reporting is to begin 6 months after publication of the final guidance. Premarket review requirements begin after the high-risk (Class III) LDTs are completed 5 years after publication of the final guidance, and phase-in over 4 years.

Guidance at page 13.

LDT Devices of Higher Concern to FDA

The Guidance states that FDA will initially focus its enforcement by first generally enforcing the premarket review requirements beginning 12 months after publication of the final guidance for the following LDTs:

  1. LDTs with the same intended use as a cleared or approved product companion diagnostic;
  2. LDTs with the same intended use as an FDA-approved Class III medical device; and
  3. Certain LDTs for determining the safety or efficacy of blood or blood products.

Guidance at page 24.

The Guidance notes that for 12 months following publication of the final guidance, FDA intends to exercise enforcement discretion with respect to premarket review requirements for currently marketed LDTs in the above three categories. FDA will begin enforcing premarket review requirements for these categories at the end of the 12-month period. If a premarket submission is timely made, the FDA will exercise enforcement discretion when the submission is under review. The Guidance also states that FDA intends to begin enforcing premarket review requirements immediately upon publication of the final guidance for all new LDTs in the above three categories.

Notice and Comments

The public is invited to submits comments and suggestions regarding the Guidance by February 2nd, 2015. Written comments can be submitted to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Room 1061, Rockville Maryland 20852. Electronic comments can be submitted to http://www.regulations.gov.

Devices and tests that are utilized in the practice of personalized medicine are likely considered of higher risk and of higher concern to FDA. Thus, the Guidance should be carefully reviewed for its impact on current and future device development and services.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions